Medtronic

Health Care Health Care Equipment Dublin, Ireland Last filing Jun 18, 2026 · FY2026

                    Revenue
                    FY2026
                
$36.4B
                    3y CAGR +4.0%
                    
                    +8.4%
                    
                    Net income
                    FY2026
                
$4.8B
                    Net margin +13.2%
                    
                    +3.0%
                    
                    Total assets
                    FY2025
                
$91.7B
                    
                    +1.9%
                    
                    Operating cash flow
                    FY2026
                
$7.3B
                    FCF margin +14.9%
                    
                    +4.1%

15 yrs · FY2012–FY2026 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

11 accounts · 5 years

Total assets $91.7B

Total liabilities $43.4B

Shareholders equity $48.0B

Account	2026	2025	2024	2023	2022
Assets
Accounts Receivable	—	7.1%	6.8%	6.8%	6.6%
Inventory	—	6.0%	5.8%	—	—
Prepaid Expenses	—	3.1%	2.9%	—	—
Property,Plant and Equipment	—	7.5%	6.8%	6.8%	6.1%
Goodwill	—	45.5%	45.5%	45.5%	45.5%
Intangible Assets	—	12.7%	14.7%	—	—
Other Noncurrent Assets	—	3.9%	4.5%	4.5%	4.4%
Liabilities
Accrued Liabilities	—	1.5%	1.5%	1.5%	0.9%
Long Term Debt	—	0.1%	0.1%	—	—
Other Noncurrent Liabilities	—	1.9%	1.5%	1.5%	1.9%
Equity
Common Stock	—	0.0%	0.0%	0.0%	0.0%

Income Statement

Revenue, expense, and profitability

17 accounts · 5 years

Revenue $36.4B

Operating income $6.5B

Net income $4.8B

Account	2026	2025	2024	2023	2022
IncomeStatement
Revenues Total Revenue	—	36.6%	36.0%	—	—
Expenses Cost of Revenue	—	12.7%	12.5%	—	—
Expenses Research and Development	—	3.0%	3.0%	—	—
Expenses Selling,General and Administrative	—	11.8%	11.9%	—	—
Expenses Depreciation and Amortization	—	3.1%	2.9%	—	—
Expenses Share Based Compensation	—	0.5%	0.4%	—	—
Other Income Expense Operating Income	—	6.5%	5.7%	—	—
Other Income Expense Interest Expense	—	0.8%	0.8%	0.8%	0.7%
Other Income Expense Other Income/expense	—	0.4%	0.5%	—	—
Other Income Expense Income Before Tax	—	6.1%	5.4%	—	—
Income Tax Income Tax Expense	—	1.0%	1.3%	—	—
net Income net Income	—	5.1%	4.1%	—	—
net Income Comprehensive Income	—	4.0%	4.3%	—	—
Earnings Per Share Basic Eps	—	0.0%	0.0%	—	—
Earnings Per Share Diluted Eps	—	0.0%	0.0%	—	—
Earnings Per Share Weighted Average Shares Basic	—	1.4%	1.5%	—	—
Earnings Per Share Weighted Average Shares Diluted	—	1.4%	1.5%	—	—

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 5 years

Operating cash flow $7.3B

Investing cash flow $-2.9B

Financing cash flow $-4.8B

Account	2026	2025	2024	2023	2022
CashFlow
Operating Activities net Income	—	5.1%	4.1%	4.1%	4.1%
Operating Activities Depreciation and Amortization	—	1.1%	1.1%	1.1%	1.1%
Operating Activities Stock Based Compensation	—	0.5%	0.4%	—	—
Operating Activities Deferred Income Taxes	—	-0.4%	-0.6%	-0.6%	-0.3%
Operating Activities Changes In Operating Assets and Liabilities	—	0.3%	0.2%	0.4%	0.2%
Operating Activities net Cash From Operating Activities	—	7.7%	7.5%	—	—
Investing Activities Capital Expenditures	—	2.0%	1.8%	—	—
Investing Activities Business Acquisitions	—	0.1%	0.2%	—	—
Investing Activities Purchases of Investments	—	9.0%	8.6%	—	—
Investing Activities Other Investing Activities	—	0.3%	0.3%	0.3%	-0.0%
Investing Activities net Cash From Investing Activities	—	-2.1%	-2.6%	—	—
Financing Activities Proceeds From Debt	—	3.5%	0.0%	—	—
Financing Activities Repayment of Debt	—	0.0%	0.0%	—	—
Financing Activities Repurchase of Common Stock	—	3.5%	2.4%	—	—
Financing Activities Dividends Paid	—	3.9%	4.1%	—	—
Financing Activities Proceeds From Stock Issuance	—	0.6%	0.3%	—	—
Financing Activities Other Financing Activities	—	-0.2%	-0.0%	—	—
Financing Activities net Cash From Financing Activities	—	-4.8%	-4.9%	—	—
Cash Reconciliation Effect of Exchange Rate On Cash	—	0.2%	-0.3%	—	—
Cash Reconciliation net Change In Cash	—	1.0%	-0.3%	—	—

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years

Ratio	2026	2025	2024	2023	2022
Profitability
Gross margin	+65.0%	+65.3%	+65.3%	+65.3%	+65.7%
Operating margin	+17.8%	+17.8%	+15.9%	+15.9%	+17.6%
Net margin	+13.2%	+13.9%	+11.4%	+11.4%	+12.0%
FCF margin	+14.9%	+15.5%	+16.1%	+16.1%	+14.7%
Growth
Revenue CAGR (3y)	+4.0%	+2.4%	+0.7%	+2.4%	+2.6%
Returns
ROE	—	+9.7%	+7.3%	+7.3%	+7.3%
ROA	—	+5.1%	+4.1%	+4.1%	+4.1%
ROIC	—	+10.2%	+7.9%	+10.3%	+11.0%
Liquidity
Current ratio	—	1.85x	2.03x	2.03x	2.39x
Quick ratio	—	0.68x	0.69x	0.69x	0.83x
Leverage
D/E	—	0.90x	0.79x	0.79x	0.76x
Interest coverage	9.04x	8.17x	7.15x	7.15x	8.62x
Efficiency
Asset turnover	—	0.37x	0.36x	0.36x	0.34x
Cash conversion cycle	—	+166d	+160d	+160d	+160d

Valuation

Price against fundamentals

FY2026 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Medtronic

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history